# US 11,078,462 B2 · Perivascular stromal cells from primate pluripotent stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,078,462 B2
- Document ID: US11078462B2
- Status: Granted
- Kind: B2
- Application number: 14/625,621
- Filed: 2015-02-18
- Published: 2015-12-24
- Granted: 2021-08-03
- Earliest claimed: 2014-02-18
- Assignees: ReCyte Therapeutics, Inc.
- Applicants: ReCyte Therapeutics, Inc.
- Inventors: Jiwei Yang; Dana Larocca; Midori Greenwood-Goodwin
- Web page: https://patentgrep.com/patent/US11078462B2

## CPC

- C12N 5/0662: {Stem cells}
- C12N 5/069: {Vascular Endothelial cells}
- C12N 5/0652: {Cells of skeletal and connective tissues; Mesenchyme}
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/165: Vascular endothelial growth factor [VEGF]
- C12N 2502/28: Vascular endothelial cells
- C12N 2506/02: from embryonic cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides methods, compositions and kits for making and using pericyte-like cells or perivascular stromal cells derived from pPS cells.

## Claims

### Claim 1

An isolated population of pericyte progenitor cells comprising a CD146+/CD73+/CD133+/CD31− expression profile, wherein the cells express podoplanin and are CD34− or CD34+, and wherein the cells are not adipogenic when cultured in adipogenesis differentiation medium, are osteogenic when cultured in mesenchymal stem cell medium, and are angiogenic when cultured in endothelial cell growth medium.

### Claim 2 (depends on 1)

The isolated population of pericyte progenitor cells of claim 1, wherein the cells further express one or more of markers chosen from CD90, CD105, PDGFRβ and NG2.

### Claim 3 (depends on 1)

The isolated population of pericyte progenitor cells of claim 1, wherein the cells are CD34−.

### Claim 4 (depends on 1)

A kit comprising the isolated population of pericyte progenitor cells of claim 1 and endothelial cells.

### Claim 5 (depends on 4)

The kit of claim 4, wherein the pericyte progenitor cells and the endothelial cells are at a ratio of 1:3.

### Claim 6 (depends on 5)

The kit of claim 5, wherein the endothelial cells are HUVEC cells.

### Claim 7 (depends on 4)

The kit of claim 4, further comprising culture media, optionally also comprising substrate or extracellular matrix for culturing cells.

### Claim 8 (depends on 7)

The kit of claim 7, further comprising an anti- or pro-angiogenic factor.